0001628280-26-026604.txt : 20260422 0001628280-26-026604.hdr.sgml : 20260422 20260422165333 ACCESSION NUMBER: 0001628280-26-026604 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260421 FILED AS OF DATE: 20260422 DATE AS OF CHANGE: 20260422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hyep Ivan CENTRAL INDEX KEY: 0002034668 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42271 FILM NUMBER: 26884486 MAIL ADDRESS: STREET 1: BICARA THERAPEUTICS INC. STREET 2: 116 HUNTINGTON AVENUE, SUITE 703 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bicara Therapeutics Inc. CENTRAL INDEX KEY: 0002023658 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 116 HUNTINGTON AVENUE SUITE 703 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-468-4219 MAIL ADDRESS: STREET 1: 116 HUNTINGTON AVENUE SUITE 703 CITY: BOSTON STATE: MA ZIP: 02116 4 1 wk-form4_1776891211.xml FORM 4 X0609 4 2026-04-21 0 0002023658 Bicara Therapeutics Inc. BCAX 0002034668 Hyep Ivan false BICARA THERAPEUTICS INC. 116 HUNTINGTON AVENUE, SUITE 703 BOSTON MA 02116 0 1 0 0 Chief Financial Officer 1 Common Stock 2026-04-21 4 M 0 9200 3.7898 A 154555 D Common Stock 2026-04-21 4 S 0 9200 23.0015 D 145355 D Stock Option (Right to Buy) 3.7898 2026-04-21 4 M 0 9200 0 D 2033-04-05 Common Stock 9200 39744 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.68 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. /s/ Lara Meisner, Attorney-in-Fact 2026-04-22